The 1955 Nobel Prize for Oxytocin Synthesis

Category	Research
Also known as	du Vigneaud Nobel, 1955 Nobel Chemistry
Last updated	2026-04-14
Reading time	3 min read
Tags	historynobel-prizeoxytocinpeptide-synthesis

Overview

The 1955 Nobel Prize in Chemistry was awarded to Vincent du Vigneaud "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone." The citation recognized both a career-long program on sulfur biochemistry — including biotin, methionine, and glutathione — and the landmark 1953 total synthesis of oxytocin.

The oxytocin synthesis was the first time a biologically active peptide hormone had been assembled in the laboratory from its constituent amino acids with retention of its physiological activity. For the Nobel Committee, this achievement resolved a fundamental question: is a hormone's activity encoded entirely by its amino acid sequence, or does biology require something else? Du Vigneaud's work firmly established that the primary sequence was sufficient, which in turn justified the program of chemical peptide synthesis that has dominated hormone research ever since.

The award was handed out relatively quickly after publication (1953 synthesis → 1955 prize), reminiscent of the pace of the insulin Nobel. Both awards reflect the Nobel Committee's willingness, at moments of paradigm-shifting work, to recognize discoveries within a few years.

Key People

Vincent du Vigneaud (1901–1978): Sole recipient of the 1955 prize.
Max Bergmann: Earlier mentor whose protecting-group chemistry influenced du Vigneaud's methods.
Charles Ressler, Stuart Trippett, John M. Roeske: Du Vigneaud's key collaborators on oxytocin synthesis.
John Jacob Abel: Earlier pituitary peptide pioneer whose work set the stage.

Timeline

1906: Henry Dale identifies oxytocic activity in posterior pituitary extracts.
1928: Oliver Kamm separates oxytocin and vasopressin activities.
1950: Du Vigneaud proposes the disulfide-bridged nonapeptide structure of oxytocin.
1953: Total synthesis of oxytocin is reported.
1954: Vasopressin synthesis follows.
1955: Nobel Prize in Chemistry awarded.

Background

The 1955 Nobel Prize crystallized a two-decade convergence in biochemistry. Sulfur chemistry — including the metabolism of homocysteine, the chemistry of disulfide bonds, and the biosynthesis of vitamin co-factors — had been a long-standing interest of du Vigneaud's laboratory. When attention turned to posterior pituitary peptides, it was the disulfide-bridged structure of oxytocin that made the molecule a natural fit for his group's expertise.

The oxytocin synthesis was a technical tour de force. It required coupling nine amino acids in the right sequence, with reliable protection of side-chain functional groups, controlled disulfide bond formation, and sensitive bioassays to confirm identity with natural oxytocin. Many of the reagents and strategies used survive in modern solid-phase peptide synthesis.

Modern Relevance

The 1955 prize anticipates the entire era of synthetic peptide pharmaceuticals. Modern drugs like desmopressin, carbetocin, leuprolide, and semaglutide — all made synthetically and all designed to mimic, extend, or selectively inhibit natural peptide activities — descend from the methodological and conceptual framework du Vigneaud established.

The prize also illustrates the Nobel tradition of honoring the combination of methodological and discovery achievements. The citation explicitly ties sulfur biochemistry to the oxytocin synthesis, recognizing that scientific programs often produce their most important results as culminations of long methodological development. For more, see vincent-du-vigneaud and first-synthetic-oxytocin.